| |
HPV testing with genotyping triage
|
HPV testing with cytology triage
|
|---|
|
HPV-16/18
|
Non-16-18 HPV genotypes
|
|---|
|
Women who attended immediate colposcopy adherence to the protocola
|
|
CIN2+, n/N (%)
|
1922/13 488 (17.3)
|
902/7167 (13.8)
|
870/4127 (24.1)
|
|
aOR (95% CI)
|
1.32 (1.22–1.43)
|
Ref (1.00)
|
1.96 (1.77–2.16)
|
|
Colposcopies per CIN2+ detection
|
5.8
|
7.2
|
4.1
|
|
CIN2 or 3, n/N (%)
|
1736/13 488 (15.6)
|
861/7167 (13.1)
|
785/4127 (21.8)
|
|
aOR (95% CI)
|
1.24 (1.14–1.34)
|
Ref (1.00)
|
1.82 (1.64–2.01)
|
|
ICC, n/N (%)
|
186/13 488 (1.7)
|
41/7167 (0.6)
|
85/4127 (2.4)
|
|
aOR (95% CI)
|
2.75 (2.00–3.78)
|
Ref (1.00)
|
3.64 (2.55–5.20)
|
|
Women who needed intensified screening but attended immediate colposcopy b
|
|
CIN2+, n/N (%)
|
NA
|
102/3507 (2.9)
|
83/1673 (5.0)
|
|
aOR (95% CI)
|
NA
|
Ref (1.00)
|
1.92 (1.38–2.67)
|
|
Colposcopies per CIN2+ detection
|
NA
|
34.5
|
20.0
|
|
CIN2 or 3, n/N (%)
|
NA
|
91/3507 (2.6)
|
67/1673 (4.0)
|
|
aOR (95% CI)
|
NA
|
Ref (1.00)
|
1.68 (1.18–2.39)
|
|
ICC, n/N (%)
|
NA
|
11/3507 (0.3)
|
16/1673 (1.0)
|
|
aOR (95% CI)
|
NA
|
Ref (1.00)
|
3.94 (1.61–9.63)
|
- Note: HPV human papillomavirus, aOR adjusted odds ratio, CI confidential interval, CIN2+ cervical intraepithelial neoplasia 2 grade or worse, ICC invasive cervical cancer, Ref reference, NA not applicable. aThese women included those who were HPV-16 or HPV-18 positive, non-16-18 high-risk HPV positive with abnormal cytology, and any HPV positive with abnormal cytology. bThese women included those who were non-16-18 high-risk HPV positive with negative cytology and any HPV positive with negative cytology. aOR was calculated by using multivariate logistic regression adjusted for age, ever screening, and income classification
